PTC Therapeutics | PTCT - Interest Expense On Debt


PTC Therapeutics reported $50.58M in Interest Expense on Debt for its fiscal quarter ending in December of 2025.





Interest Expense On Debt Change Date
Acadia Pharmaceuticals USD 0 4.12M Sep/2024
Alnylam Pharmaceuticals USD 129.34M 84.94M Dec/2025
Amgen USD 653M 32M Dec/2025
BioCryst Pharmaceuticals USD 14.14M 5.53M Dec/2025
Biogen USD 72.6M 12.6M Jun/2025
BioMarin Pharmaceutical USD 2.78M 199K Dec/2025
Cytokinetics USD 30.33M 4.01M Dec/2025
Daiichi Sankyo JPY 2.16B 1.33B Dec/2025
Enanta Pharmaceuticals USD 1.96M 620K Dec/2024
Esperion Therapeutics USD 22.64M 585K Dec/2025
Gilead Sciences USD 255M 1000K Dec/2025
Incyte USD 582K 10K Dec/2025
Ionis Pharmaceuticals USD 18M 0 Dec/2025
Ironwood Pharmaceuticals USD 8.74M 506K Dec/2024
Karyopharm Therapeutics USD 12.62M 1.24M Dec/2025
Novartis USD 304M 23M Dec/2025
Pfizer USD 711M 59M Dec/2025
PTC Therapeutics USD 50.58M 2.59B Dec/2025
Puma Biotechnology USD 3.37M 11K Jun/2024
Roche Holding CHF 304M 7.5M Jun/2025
Sangamo BioSciences 97.56M 11.39M Jun/2025
Sarepta Therapeutics USD 7.56M 2.33M Sep/2025
TG Therapeutics USD 6.53M 187K Dec/2025
Ultragenyx Pharmaceutical USD 19M 4.85M Dec/2025
Vertex Pharmaceuticals USD 3.3M 0 Dec/2025
Xencor USD 7.35M 311K Dec/2025